Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to allegations that Elevance Health made false or misleading statements regarding the impact of Medicaid redetermination on its financial guidance and cost trends [4]. - The lawsuit claims that Elevance misrepresented the adequacy of premium rates negotiated with states, failing to disclose the rising acuity and utilization of Medicaid members [4]. - Investors are encouraged to join the class action by contacting Rosen Law Firm, with a lead plaintiff application deadline set for July 11, 2025 [2][5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors [3]. - Founding partner Laurence Rosen has received recognition as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [3].

Core Viewpoint - A class action lawsuit has been filed against Krispy Kreme, Inc. for misleading statements regarding its partnership with McDonald's and the subsequent decline in product demand, with a lead plaintiff deadline set for July 15, 2025 [1][4]. Group 1: Lawsuit Details - The lawsuit alleges that Krispy Kreme made false and misleading statements about the demand for its products at McDonald's locations, which significantly declined after the initial marketing launch [4]. - It is claimed that the declining demand at McDonald's was a key factor in the drop in average sales per door per week, and that the partnership with McDonald's was not profitable [4]. - The lawsuit states that these issues posed a substantial risk to maintaining the partnership with McDonald's and led to a pause in Krispy Kreme's expansion into new locations [4]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions of dollars for investors [3]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in the number of settlements since 2013 [3]. Group 3: Participation Information - Investors who purchased Krispy Kreme securities during the class period can join the class action without any out-of-pocket fees through a contingency fee arrangement [1][2]. - Interested parties can find more information and join the class action by visiting the provided link or contacting the firm directly [2][5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Rocket Pharmaceuticals provided misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing material adverse facts, including the risk of Serious Adverse Events (SAEs) [5]. - It is claimed that Rocket Pharmaceuticals amended the trial protocol without informing shareholders, leading to artificially inflated stock prices, which resulted in investor damages when the true information was revealed [5].

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Vestis Corporation (NYSE: VSTS) between May 2, 2024 and May 6, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Vestis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO N ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 21, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customers' ad spending to closed platforms where DoubleVerify's capabilities were limited [5]. - It is claimed that the company overbilled customers for ad impressions served to declared bots and that its risk disclosures were materially false and misleading [5]. - The lawsuit asserts that the defendants' positive statements about DoubleVerify's business lacked a reasonable basis, leading to investor damages when the true details emerged [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Krispy Kreme, Inc. securities between February 25, 2025, and May 7, 2025, of the July 15, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Krispy Kreme, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - Investors wishing to serve as lead plaintiff must file with the court by July 15, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that during the class period, Krispy Kreme made false and misleading statements regarding the demand for its products at McDonald's locations, which declined materially after the initial marketing launch [4] - It is claimed that the partnership with McDonald's was not profitable, leading to a pause in expansion into new locations and that the positive statements made by the defendants were materially misleading [4]

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADSs”) of Reckitt Benckiser Group PLC (OTC: RBGLY) between January 13, 2021 through July 28, 2024, both dates inclusive (the “Class Period”), of the important August 4, 2025 lead plaintiff deadline. SO WHAT: If you purchased Reckitt ADSs you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme ...

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Red Cat Holdings, Inc. (NASDAQ: RCAT) between March 18, 2022 and January 15, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Red Cat securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Iovance Biotherapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit claims that during the Class Period, Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi, leading to higher costs and lower revenue [3]. - The lawsuit alleges that the delays in treatment timelines and ineffective patient identification by Iovance's sales team resulted in increased patient drop-offs, which negatively impacted the company's financial performance [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bitfarms Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline on July 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Bitfarms securities between March 21, 2023, and December 9, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the July 8, 2025 deadline [2][4]. - The lawsuit alleges that Bitfarms made false and misleading statements regarding its financial reporting and internal controls, leading to potential misstatements in financial statements that may require restatement [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].